Last reviewed · How we verify

NCT03955016

Rehabilitation for Patients With Pulmonary Hypertension

Status unknown NA Last updated 10 October 2019
What this trial tests

NA trial testing Pulmonary rehabilitation in Pulmonary Hypertension in 20 participants. Status unknown.

Timeline
13 November 2018
Primary endpoint
1 November 2020
1 November 2020

Quick facts

Lead sponsorKU Leuven
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment20
Start date13 November 2018
Primary completion1 November 2020
Estimated completion1 November 2020
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

KU Leuven — full company profile →

Who can join

18 and older, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the impact of a personalized, partly supervised rehabilitation program on the exercise capacity in patients with pulmonary hypertension. The rehabilitation program consists of 2 weeks inpatient, 2 weeks ambulatory and 11 weeks home based rehabilitation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Exercise-based rehabilitation programmes for pulmonary hypertension.
    Morris NR, Kermeen FD, Jones AW, Lee JY, et al · · 2023 · cited 29× · PMID 36947725 · DOI 10.1002/14651858.cd011285.pub3

Verify or expand the search:

Other trials of Pulmonary rehabilitation

Trials testing the same drug.

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

Other KU Leuven trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03955016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing